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Background: Aquaporins AQP1 and AQP5 are highly expressed in the lung. Recent studies have shown that the
expression of these proteins may be mechanistically involved in the airway inflammation and in the pathogenesis
of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the expression of AQP1
and AQP5 in the bronchial tissue and the lung parenchyma of patients with COPD and COPD-resistant smokers.
Methods: Using a case–control design, we selected a group of 15 subjects with COPD and 15 resistant smokers
(smokers without COPD) as a control, all of whom were undergoing lung resection surgery due to a lung neoplasm.
We studied the expression of AQP1 and AQP5 in the bronchial tissue and the lung parenchyma by means of
immunohistochemistry and reverse-transcription real-time polymerase chain reaction. Tissue expression of AQP1 and
AQP5 was semi-quantitatively assessed in terms of intensity and expression by immunohistochemistry using a 4-point
scale ranging from 0 (none) to 3 (maximum).
Results: There were no significant differences in gene expression between COPD patients and resistant smokers both
in the bronchial tissue and in the lung parenchyma. However, AQP1 gene expression was 2.41-fold higher in the
parenchyma of smokers with COPD compared to controls, whereas the AQP5 gene showed the opposite pattern, with
a 7.75-fold higher expression in the bronchus of smokers with COPD compared with controls. AQP1 and AQP5 proteins
were preferentially expressed in endothelial cells, showing a higher intensity for AQP1 (66.7% of cases with an intensity
of 3, and 93.3% of subjects with an extension of 3 among patients with COPD). Subtle interstitial disease was associated
with type II pneumocyte hyperplasia and an increased expression of AQP1.
Conclusions: This study provides pilot observations on the differences in AQP1 and AQP5 expression between COPD
patients and COPD-resistant smokers. Our findings suggest a potential role for AQP1 in the pathogenesis of COPD.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by a chronic airflow limitation as a conse-
quence of an enhanced inflammatory response to the
inhalation of toxics and fumes, the most common one
being tobacco smoke. Although tobacco smoke is the* Correspondence: ccalero-ibis@us.es
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unless otherwise stated.main risk factor for COPD, not all smokers develop the
disease, and this group comprises the so-called resistant
smokers. COPD is currently considered a major cause of
morbidity and mortality worldwide [1] and has a devastat-
ing impact on health status. Much attention has been de-
voted to studying the expression of inflammatory markers
in the lung to find biomarkers of diagnostic or prognostic
value and to identify new potential therapeutic targets [2].
Aquaporins (AQPs) are a group of proteins discovered
in the early 1990s that form specific channels for water
transport across cells [3]. Several members of this familyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plants, with at least 13 different AQPs in humans [4].
Among these proteins, AQP5 is most highly expressed
in the lung. In addition to contributing to the water per-
meability of the cell membrane, AQPs participate in
nerve signal transduction, skin flexibility, fat metabolism,
membrane permeability to gases, and cell migration and
proliferation [5]. Although no studies have assessed the
expression of AQP5 in lung tissues from patients with
COPD, a polymorphism in the AQP5 gene has been
associated with lung function decline in COPD, the hall-
mark of disease progression. Taken together, these re-
sults suggest that the expression of this protein could be
mechanistically involved in COPD pathogenesis or in-
flammatory expression [6].
The expression of AQP1 in lung carcinoma and
pleural mesotheliomas has been recently studied. The
findings indicated an increase in the expression of this
protein in adenocarcinomas and mesotheliomas, but not
in other lung carcinomas. Our results also showed high
expression of AQP1 in the small blood vessels surround-
ing the tumor, suggesting an important role of AQP1 in
tumor angiogenesis [7].
Despite these observations, the tissue expression of
AQP1 and AQP5 in COPD patients is unknown. Using
a case–control design, we selected a group of smokers
with COPD and a group of COPD-resistant smokers, all
of whom were undergoing lung resection surgery due to
a lung neoplasm. The expression of AQP1 and AQP5
in the bronchial tissue and the lung parenchyma was
investigated by means of immunohistochemistry and
reverse-transcription real-time polymerase chain reaction
(RT-qPCR). The tissue expression of AQP1 and AQP5 was
then compared in patients with COPD and in COPD-
resistant smokers.
Methods
The present study was designed as an observational
case–control pilot study. A total of 15 smokers with
COPD and 15 COPD-resistant smokers undergoing lung
surgery (lobectomy or pneumonectomy, due to a local-
ized primary lung neoplasm, were enrolled. The study
followed the tenets of the Declaration of Helsinki and
was approved by our institutional review board. Written
informed consent was obtained from all participants.
Patients > 40 years were consecutively selected until
we obtained 15 cases per group on the day of admission
before lung surgery. A detailed standardized questionnaire
was administered to each patient to identify the clinical
and functional diagnostic criteria for COPD. According to
the international guidelines [8], patients with a tobacco
history > 10 pack/years and a post-bronchodilator spir-
ometry showing a ratio of forced expiratory volume in
the first second (FEV1)/forced vital capacity (FVC) below0.7 were considered COPD patients. By contrast, subjects
with a FEV1/FVC ≥ 0.7 were considered resistant smokers.
The severity of COPD was determined based on FEV1
expressed as the percentage of the predicted value, accord-
ing to the Global Initiative for Obstructive Lung Disease
(GOLD) guidelines [8]. Patients with any other lung dis-
ease associated with airflow obstruction or any chronic
inflammatory disease were not enrolled in the study. Simi-
larly, we excluded patients for whom the duration of the
surgery (from the opening of the cutaneous layer until
the extraction of the sample) exceeded three hours. Once
the anatomical lobe was extracted, a portion of macro-
scopically healthy bronchus and parenchyma samples,
distant from the primary lesions, was transferred to a
sterile satellite table on ice and processed as described
below. The bronchial tissue and the lung parenchyma
were selected as the primary tissues involved in the patho-
genesis of COPD.
Gene expression
AQP gene expression was analyzed in the tissue samples
by RT-qPCR, which included three phases: RNA extrac-
tion, reverse transcription to cDNA, and gene amplifica-
tion by PCR. RNA was isolated from fresh tissue with a
TriSure kit (Bioline, London, UK) according to the manu-
facturer’s protocol. The RNA was treated with RNase-free
DNase I using a commercial kit (QIAgen GmbH, Hilden,
Germany) to remove any residual genomic DNA that may
have been present in the RNA. cDNA was synthesized
using an iScript kit (Bio-Rad, Hercules, CA, USA). Each re-
action was performed in duplicate using a final reaction
volume of 25 μL: 2 μL of cDNA (40 ng/μl), 12.5 μL Sybr
green PCR master mix (Stratagene, La Jolla, CA, USA) and
10.5 μL primers/H2O. RT-qPCR was performed using an
MX3005P system (Stratagene) at 95°C for 30 sec, 60°C for
1 min, and 72°C for 30 sec. Gene amplification was nor-
malized to 18S rRNA. Data analysis was performed using
the 2-ΔΔCt method [9]. The primers used are listed in
Table 1.
Immunohistochemistry
Since all bronchial samples were utilized for gene expres-
sion studies, bronchial immunohistochemistry was not
feasible in this study. Parenchymal samples examined
were obtained from formalin-fixed, paraffin-embedded
tissue. Tissue slices (5 μm) were cut with a microtome
and mounted on microscope slides. The immunohisto-
chemical procedure started with removal of the paraffin
from tissue slices by immersion in xylene and rehydra-
tion through a series of decreasing dilutions of ethanol.
Endogenous peroxidase activity was blocked by preincu-
bation of slices in 3% H2O2. Heat-induced epitope re-
trieval for AQP1 was carried out by incubating tissue
sections at 65°C for 1 h in 10 mM sodium citrate (pH 6).




















Male sex (n) 14 (93.3) 10 (66.7) NS
Age (years) 62.5 (9.8) 68.3 (7.4) NS
Active smokers (n) 3 (20) 3 (20) NS
Body mass index (Kg/m2) 26.1 (4.4) 28.5 (4.2) NS
FVC (mL) 3,274.1 (1,108.5) 3,016 (310.2) NS
FVC (%) 92.8 (15.9) 86.7 (20.9) NS
FEV1 (mL) 2,459.1 (775.5) 1,717 (574.6) 0.021
FEV1 (%) 92.8 (33.1) 72 (13) 0.031
FEV1/FVC (%) 76.2 (6.6) 62.5 (4.8) < 0.001
Resection type NS
- Pneumonectomy or (n) 4 (26.7) 2 (13.3)
- Lobectomy (n) 11 (73.3) 12 (80.0)
- Atypical (n) 0 1 (6.7)
Pathology: NS
- Squamous carcinoma (n) 6 (40.0) 8 (53.3)
- Adenocarcinoma (n) 5 (33.3) 7 (46.7)
- Other (n) 2 (13.3) 0
- Benign tumor (n) 1 (6.7) 0
- Non-neoplastic disease (n) 1 (6.7) 0
Data are expressed as means (standard deviations) or absolute (relative)
frequencies, as appropriate. FEV1, forced expired volume in 1 second; FVC,
Forced vital capacity; NS, not significant.
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3 minutes in 4.5 mM Tris (pH 8) and 1 mM EDTA.
Rabbit polyclonal anti-AQP1 (1:500 dilution; Abcam,
Cambridge, UK) and rabbit polyclonal anti-AQP5 (1:50
dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
antibodies were applied to the tissues. All specimens
were then treated by the two-step EnVision plus Dual
Link System-HRP (DakoCytomation, Dako, Glostrup,
Denmark) procedure using goat anti-rabbit immunoglob-
ulins conjugated to a peroxidase-labelled polymer and a
DAB-substrate-DAB-chromogen to develop brown pre-
cipitates. Sections were photographed using an AX70-
Olympus microscope equipped with an Olympus DP10
camera. No staining was observed when the primary
antibody was omitted. Counter-staining was performed
with haematoxylin, and the sections were analyzed
by an experienced pathologist. Immunohistochemistry
was semi-quantitatively evaluated by an experienced lung
pathologist using a modified H-scoring system [10]. The
intensity and the extent of the expression were evaluated
in the tissue vessels, type II pneumocytes, and basal cells
using a scale ranging from 0 (none) to 3 (maximum).
The intensity was scored as follows: 0: no expression; 1:
non-uniform and weak expression; 2: uniform but weak
expression; 3: uniform and strong expression. The extent
of expression was coded as 0: none; 1: focal expression
(<33%); 2: zonal expression (33–66%); 3: diffuse expres-
sion (>66%).
Statistical analysis
The statistical computations were carried out using the
Statistical Package for the Social Sciences (SPSS, IBM
Corporation, Somers, NY, USA) version 19.0. Categorical
variables were described using the absolute and relative
frequencies of their categories. Quantitative variables
were expressed as means and standard deviations. The
expression of the AQP1 and AQP5 genes both in the
bronchial tissue and the lung parenchyma was compared
between cases and controls using the Mann–Whitney U
test. Comparisons between the two anatomical locations
were performed with the Wilcoxon test. The differences
in gene expression were graphically depicted using a bar
plot representing the mean with standard error bars.
The alpha error was set at 0.05 (two-tailed).Results
The sample included 15 COPD patients (93.3% males,
mean age: 68 years, mean FEV1: 72%) and 15 resistant
smokers (66.7% males, mean age 62 years, mean FEV1:
92%) as control. The general characteristics of the study
participants are summarized in Table 2. Four COPD
patients (26.7%) were in GOLD stage 1, whereas 11
(73.3%) were categorized as GOLD stage 2. In the COPD
group, 4 (26.7%) patients were under treatment with a
fixed-dose combination of an inhaled corticosteroid plus
a long-acting β2 agonist, whereas 3 (20%) patients were
receiving tiotropium. One patient was diagnosed with
a neuroendocrine carcinoma, whereas another subject
had an adenosquamous carcinoma. Two patients had
a final pathological diagnosis of benign lung disease (lung
adenoma, n = 1; and aspergilloma, n = 1).
Gene expression
We found no differences in gene expression in either
location between smokers with COPD and resistant
smokers for both AQP1 and AQP5. When comparing
the parenchymal expression with the bronchial one, we
observed differences according to disease status. In the
control group, the expression of AQP1 was 2.24-fold
higher in the lung parenchyma than in the bronchus; a
a)
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(Figure 1). In contrast, AQP5 gene expression showed
an opposite pattern of expression, with higher levels in
the bronchus (increases of 2.48-fold in controls and
19.4-fold in cases; Figure 2). We found no difference in
gene expression between the cases receiving any treat-
ment and those not receiving treatment or between
active and non-active smokers. Similarly, gene expres-
sion was not significantly influenced by the GOLD
severity stages of COPD or the underlying neoplasm.
Immunohistochemistry
AQP1 and AQP5 were preferentially expressed in the ves-
sel wall, showing a higher intensity for AQP1. In cases
where some subtle interstitial disease appeared, the areas
of type 2 pneumocyte hyperplasia showed an increaseda)
b)
Figure 1 Relative expression of AQP1 in the lung parenchyma
as compared to the bronchus in COPD patients and controls.
a) Controls (p = 0.088); b) COPD (p = 0.035).
b)
Figure 2 Relative expression of AQP5 in the lung parenchyma
as compared to the bronchus in COPD patients and controls.
a) Controls (p = 0.112); b) COPD (p = 0.023).AQP1 expression (Figure 3, Table 3). AQP5 was not in-
tensely expressed in patients with COPD, except in basal
cells, which showed a slight increase over the surrounding
cells (Figure 3). There were no significant associations be-
tween the clinical parameters and the immunohistochemi-
cal expression of either AQP1 or AQP5.
Discussion
The present study describes the expression of both
AQP1 and AQP5 in patients with COPD as compared to
resistant smokers. We observed a significant overexpres-
sion of AQP1 in the parenchymal tissues from smokers
with COPD. Both AQPs were mostly expressed in the
vessel wall, with an increase in type 2 pneumocytes in
smokers with COPD.
Figure 3 Immunohistochemistry of the lung parenchyma
for AQP1 (panel a) and AQP5 (panel b) in COPD patients.
The arrows indicate type 2 pneumocytes. The star shows a
blood vessel.
Table 3 Immunohistochemistry for AQP1 and AQP5: number
AQP1 Vessels Intensity = 3
Extension = 3
Type 2 pneumocytes Intensity = 3
Extension = 3
Basal cells Intensity = 3
Extension = 3
AQP5 Vessels Intensity = 3
Extension = 3
Type 2 pneumocytes Intensity = 3
Extension = 3
Basal cells Intensity = 3
Extension = 3
*χ2 test. Only p below 0.1 are shown in the Table. NS, not significant.
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50-fold higher water permeability than cells that do not
[11]. AQPs have important roles in the pathogenesis of
pulmonary diseases, especially lung cancers. Recently, a
mouse model of asthma induced by ovalbumin has been
used to study the mRNA and protein expression of
AQP1 and AQP5 [12]. The authors found that both
AQPs were significantly increased by treatment with
dexamethasone, ambroxol, and terbutaline, indicating
that AQP1 and AQP5 are closely related to pulmonary
edema but not to eosinophil infiltration or mucus secre-
tion in patients with asthma. In the present study on
COPD patients, we found an isolated increase in AQP1.
Inflammation is qualitatively different between asthma
and COPD, with a predominance of eosinophils in the
former and neutrophils in the latter [13]. This different
cell infiltration is not only a descriptive phenomenon,
but it is also associated with a different therapeutic re-
sponse, in particular to inhaled corticosteroids [14].
Some characteristics of the study participants deserve
comment. In our sample of COPD patients, four sub-
jects were taking inhaled corticosteroids. Although this
makes our group not entirely homogeneous, the results
of subgroup analyses did not reveal any significant differ-
ences in the expression of AQPs. Taken together, these
findings indicate that inhaled corticosteroids did not
have a major impact on AQP expression, at least in our
sample. The lack of inclusion of non-smokers is an im-
portant caveat inherent in our study. As we included pa-
tients who underwent surgery because of a suspected
malignancy, it is difficult to find never-smokers in this
subject group. Finally, we cannot exclude the AQP ex-
pression may differ according to the specific COPDof subjects with maximal scores for extent and intensity
Controls (n = 15) COPD (n = 15) p*
13 (86.7%) 10 (66.7%) NS
14 (93.3%) 14 (93.3%) NS
4 (26.7%) 5 (33.3%) NS
1 (6.7%) 8 (53.3%) 0.016
0 (0%) 0 (0%) NS
0 (0%) 0 (0%) NS
7 (46.7%) 5 (33.3%) 0.094
3 (20%) 2 (13.3%) NS
1 (6.7%) 0 (0%) NS
2 (13.3%) 2 (13.3%) NS
5 (33.3%) 3 (20%) NS
5 (33.3%) 8 (53.3%) NS
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AQP5 may regulate cigarette smoke-induced emphysema
by modulating the barrier and immune properties of the
epithelium [15]. Future research on AQP expression in the
airways should, therefore, include never-smokers and dif-
ferent COPD phenotypes.
There is only one interesting study from China show-
ing that the expression of AQP5 is correlated with
COPD. The authors found a correlation between a lower
expression of AQP5 in the bronchial tissue (obtained by
bronchoscopy) and an increase in the mucus secretion
(as measured by MUC5AC gene expression) [16]. Notably,
the results were confirmed by immunohistochemistry.
These results highlight the importance of phenotyping for
a correct interpretation of them. Unfortunately, an accur-
ate patient phenotyping was not available in this study. In
addition, we were unable to use a standardized question-
naire for the assessment of chronic sputum production
because at the beginning of the study no specific ad hoc
questionnaire was available [17].
In the present study, we did not find any significant
differences in aquaporins expression according to the
underlying neoplasm. Notably, we previously found
AQP1 to be differentially expressed between lung adeno-
carcinomas and squamous cell carcinomas [7]. In this
study, we sampled normal tissues localized as distant as
possible from the primary lesion. Using such an ap-
proach, we were unable to find significant differences
in both AQP1 and AQP5 expression according to the
underlying neoplasm. These results suggest that the ex-
pression of aquaporins in the normal parenchyma is not
directly influenced by the tumor type. This observation
may be explained by the impact of specific genetic poly-
morphisms. Notably, previous studies have shown that
variants in the AQP5 gene may influence the risk of de-
veloping COPD [18] and can have an impact on the rate
of lung function decline in continuous smokers with
COPD [6].
In the present study, we consistently observed an in-
creased AQP1 expression in type 2 pneumocytes, espe-
cially in areas of subtle interstitial fibrosis. Despite being
traditionally considered as two distinct conditions, grow-
ing evidence suggests that emphysema and fibrosis may
closely intertwined [19,20]. Although some biomarkers
(e.g., the KL-6 protein) have been associated with this
phenotype, the potential role of AQP1 in this context re-
mains to be determined [17]. Although the relation be-
tween fibrosis and emphysema was not the main focus
of this study, we believe that the current findings may
stimulate further studies on the potential role played by
AQP1 expressed in type 2 pneumocytes in the pathogen-
esis of the fibrosis/emphysema phenotype.
Because most AQPs are constitutively expressed on
the plasma membrane, the regulation of their functionoccurs mainly at the transcriptional level [4]. COPD is the
result of a complex interplay of genetic and environmental
factors [21]. Cigarette smoking is the major environmental
determinant of COPD, and gene–smoking interactions
have been associated with lung function in COPD and
other chronic lung diseases [22]. We found that AQP1 ex-
pression was higher in the parenchyma of patients with
COPD as compared to controls. In contrast, AQP5 was
hyperexpressed in the bronchus of patients with COPD as
compared to the controls. In this study, the medical treat-
ment did not have a significant impact on AQP gene ex-
pression. Interestingly, AQP5 was not intensely expressed
in the samples from patients with COPD, the only excep-
tion being the basal cells (which showed a slightly in-
creased expression compared to the surrounding cells). It
is noteworthy that a decreased expression of human AQP5
has been previously associated with an overproduction of
mucus in the airways of subjects with COPD and a signifi-
cant reduction in lung function [15].Conclusions
In conclusion, our observations provide preliminary evi-
dence regarding the expression of AQP1 and AQP5 in
patients with COPD as compared to COPD-resistant
smokers. In particular, AQP1 may play a role in the
pathogenesis of COPD. Further research is needed to
confirm the clinical and biological relevance of these
findings.
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